Novartis to Buy Biotech Excellergy for Up to $2 Billion
Novartis agreed to buy Excellergy, bulking up its immunology portfolio with a biotech company that specializes in treatments for food allergy and other diseases.
Where News Facts Matter
Flash News
Jesse Jackson Jr.’s comeback bid fails in Illinois primary
AIPAC, AI money propels Melissa Bean to comeback victory in Illinois
iHeartRadio Music Awards 2026: Complete Winners List
Private equity’s worst fundraising slump in a decade
Mexico’s navy searches for 2 Cuba-bound aid boats that are missing
Iran’s harder-to-hunt long-range missiles are taking greater toll
China’s Moonshot AI Seeks Listing in Hong Kong Under Heightened Scrutiny
Novartis to Buy Biotech Excellergy for Up to $2 Billion
Arizona beats Arkansas by 21 in NCAA tournament Sweet 16
2026 NFL draft team needs: Depth chart holes, prospect fits
Friday, March 27, 2026